Latest Caspase Stories
- Data on novel pro-apoptotic agent presented at the 100th Annual Meeting of the American Association for Cancer Research - - University of Pennsylvania data on chemotherapy resistance patterns in neuroblastoma cell lines, highlighting AT-101's inhibition of Mcl-1, also presented - MALVERN, Pa., April 21 /PRNewswire/ -- Ascenta Therapeutics announced today that the results of preclinical studies of its orally-active, small molecule, pro-apoptotic agent, AT-406, have been presented at the...
Diabetes and eczema may appear to be two completely unrelated diseases. But UC San Diego biologists have uncovered what appears to be a crucial biochemical link between the two.
U.S. researchers have discovered a new route through which Alzheimer's disease may either trigger or maintain the destruction of brain cells.
Medicinal plants have been used as traditional remedies for hundreds of years - Among them, S. barbata has been traditionally used in treatment of hepatitis, inflammation, osteomyelitis and gynecological diseases in China.
Pre-clinical studies presented at the 9th International Conference on Membrane Redox Systems in Wellington New Zealand this week demonstrate that Novogen's NV-128 (a novel mTOR inhibitor), when used in combination with the Marshall Edwards, Inc.'s Phase III anti-ovarian cancer drug, phenoxodiol, produces potent synergistic anti-cancer activity against non-small cell lung carcinoma cell lines (NSCLC).
By Bacqueville, Daniel Mavon, Alain ABSTRACT In the present study, a convenient and easy-to-handle skin organ culture was developed from domestic pig ears using polycarbonate Transwell(R) culture inserts in 12-well plate.
Neurologix, a biotechnology company engaged in the development of gene therapies for the brain and central nervous system, and Aegera Therapeutics, a private clinical stage company focused on oncology and neuropathic pain, have executed an exclusive license agreement.
By Vaux, David Proteins that cause cell death in insects are showing promise as anti-cancer drugs. Every second, about a million of our cells complete the process of cell division to generate an extra million cells.
BOTHELL, Wash., Aug. 7, 2008 (PRIME NEWSWIRE) -- Sonus Pharmaceuticals, Inc. (Nasdaq:SNUS) announced today that it has signed an exclusive in-licensing agreement with Bayer HealthCare LLC for development of a family of compounds known as caspase activators presently in preclinical research.
GNI and EpiCept have reached an agreement to develop a new therapeutic drug, EP1013, in Asia, Australia, and New Zealand, for late-stage viral infection-induced hepatitis. Under the agreement, EpiCept will retain the rights in the rest of the world.
- A serpent whose bite was fabled to produce intense thirst.